Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2226)	2/22/2008 10:22:00 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

NGEN was up 48.7% & is still up 40% on volume > 1M already > 2x its ADV. bigcharts.marketwatch.com Dutton Associates initiated coverage with a Strong Speculative Buy rating and a target of $1.00 It said that the molecular diagnostic market that NGEN is developing has a potential of about $2.5B/yr with a projected 15% annual growth rate. Its rapid point-of-care diagnostics could also be a $2B market. NGEN has 4Qs of significantly improved revenues & was able to trim some of its losses in the first 2Qs of the current Yr., albeit the 3rdQ losses were unchanged. The short ratio came down about 14% but is still around 2x its ADV. Will see if the stock can make a base at the $0.50 level.<g> It the stock could get back to $1 it would be a good % gain. The March 2000 H was $101.94 <g> bigcharts.marketwatch.com Bernard